Advertisement
Screener

Serina Therapeutics, Inc. (SER) Interest Expense Nonoperating

2.8 / 5 stars · 68/120 Roast Me

Serina Therapeutics, Inc. Interest Expense Nonoperating

Serina Therapeutics, Inc. (SER) reported Interest Expense Nonoperating of $203.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.

Financial Statements › Expense Statement › Interest Expense

us-gaap:InterestExpenseNonoperating · last filed 2026-08-13

  • Serina Therapeutics, Inc. interest expense nonoperating for the quarter ending 2026-06-30 was $203.00K, a 2155.56% increase year-over-year.
  • Serina Therapeutics, Inc. interest expense nonoperating for the quarter ending 2026-03-31 was $189.00K.
  • Serina Therapeutics, Inc. interest expense nonoperating for the quarter ending 2025-12-31 was $198.00K, a 1064.71% increase year-over-year.
  • Serina Therapeutics, Inc. interest expense nonoperating for the quarter ending 2025-09-30 was $6.00K, a 62.50% decline year-over-year.
  • Serina Therapeutics, Inc. interest expense nonoperating for fiscal 2025 was $213.00K, a 59.51% decline from fiscal 2024.
  • Serina Therapeutics, Inc. interest expense nonoperating for fiscal 2024 was $526.00K, a 5.73% decline from fiscal 2023.
  • Serina Therapeutics, Inc. interest expense nonoperating for fiscal 2023 was $558.00K.
Period endInterest Expense Nonoperating 3 monthInterest Expense Nonoperating 3 month as first filedInterest Expense Nonoperating 6 monthInterest Expense Nonoperating 6 month as first filedInterest Expense Nonoperating 9 monthInterest Expense Nonoperating 12 month
2026-06-30$203.00K
10-Q · filed 2026-08-13
$392.00K
10-Q · filed 2026-08-13
$590.00K
derived: sum of 3 quarters · filed 2026-08-13
$596.00K
derived: sum of 4 quarters · filed 2026-08-13
2026-03-31$189.00K
10-Q · filed 2026-05-14
$387.00K
derived: sum of 2 quarters · filed 2026-05-14
$393.00K
derived: sum of 3 quarters · filed 2026-05-14
$402.00K
derived: sum of 4 quarters · filed 2026-08-13
2025-12-31$198.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25
$204.00K
derived: sum of 2 quarters · filed 2026-03-25
$213.00K
derived: sum of 3 quarters · filed 2026-08-13
$213.00K
10-K · filed 2026-03-25
2025-09-30$6.00K
10-Q · filed 2025-11-13
$15.00K
derived: sum of 2 quarters · filed 2026-08-13
$15.00K
10-Q · filed 2025-11-13
$32.00K
derived: sum of 4 quarters · filed 2026-08-13
2025-06-30$9.00K
10-Q · filed 2026-08-13
$9.00K
10-Q · filed 2026-08-13
$26.00K
derived: sum of 3 quarters · filed 2026-08-13
$42.00K
derived: sum of 4 quarters · filed 2026-08-13
2025-03-31$0.00
10-Q · filed 2026-05-14
$17.00K
derived: sum of 2 quarters · filed 2026-05-14
$33.00K
derived: sum of 3 quarters · filed 2026-05-14
$340.00K
derived: sum of 4 quarters · filed 2026-05-14
2024-12-31$17.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25
$33.00K
derived: sum of 2 quarters · filed 2026-03-25
$340.00K
derived: sum of 3 quarters · filed 2026-03-25
$526.00K
10-K · filed 2026-03-25
2024-09-30$16.00K
10-Q · filed 2025-11-13
$323.00K
derived: sum of 2 quarters · filed 2025-11-13
$509.00K
10-Q · filed 2025-11-13
$685.00K
derived: sum of 4 quarters · filed 2025-11-13
2024-06-30$307.00K
10-Q · filed 2025-08-11
$242.00K
10-Q · filed 2024-08-09
$493.00K
10-Q · filed 2025-08-11
$341.00K
10-Q · filed 2024-08-09
$669.00K
derived: sum of 3 quarters · filed 2025-08-11
$769.00K
derived: sum of 4 quarters · filed 2025-08-11
2024-03-31$186.00K
10-Q · filed 2025-05-08
$362.00K
derived: sum of 2 quarters · filed 2025-05-08
$462.00K
derived: sum of 3 quarters · filed 2025-05-08
$570.00K
derived: sum of 4 quarters · filed 2025-05-08
2023-12-31$176.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24
$276.00K
derived: sum of 2 quarters · filed 2025-03-24
$384.00K
derived: sum of 3 quarters · filed 2025-03-24
$558.00K
10-K · filed 2025-03-24
2023-09-30$100.00K
10-Q · filed 2024-11-12
$208.00K
derived: sum of 2 quarters · filed 2024-11-12
$382.00K
10-Q · filed 2024-11-12
2023-06-30$108.00K
10-Q · filed 2024-08-09
$194.00K
10-Q · filed 2024-08-09

Similar stocks

Stock NameCountryMarket CapPE Ratio
Clene Inc. (CLNN)United States$0.054B-1.99
HERON THERAPEUTICS, INC. /DE/ (HRTX)United States$0.055B-2.38
Xilio Therapeutics, Inc. (XLO)United States$0.052B
Annovis Bio, Inc. (ANVS)United States$0.056B-1.58
NOMAD POWER SOLUTIONS, INC. (NMAD)United States$0.058B
Boundless Bio, Inc. (BOLD)United States$0.059B-0.88
Elicio Therapeutics, Inc. (ELTX)United States$0.049B
Lite Strategy, Inc. (LITS)United States$0.049B
Dogwood Therapeutics, Inc. (DWTX)United States$0.049B
TALPHERA, INC. (TLPH)United States$0.060B